Sudhakar Katakam

Array ( [id] => 19503826 [patent_doc_number] => 12115224 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Polypeptide conjugates for intracellular delivery of stapled peptides [patent_app_type] => utility [patent_app_number] => 17/817836 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 36 [patent_no_of_words] => 22181 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19367392 [patent_doc_number] => 12059453 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Blood plasma fractions for use in muscle regeneration [patent_app_type] => utility [patent_app_number] => 17/881244 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 14864 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483503 [patent_doc_number] => 20230210800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES [patent_app_type] => utility [patent_app_number] => 17/880023 [patent_app_country] => US [patent_app_date] => 2022-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17880023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077379 [patent_doc_number] => 20220402991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => NOVEL GLP-1 ANALOGUES [patent_app_type] => utility [patent_app_number] => 17/816577 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281780 [patent_doc_number] => 20230097252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => LIGASE FUSION PROTEINS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/815371 [patent_app_country] => US [patent_app_date] => 2022-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18183737 [patent_doc_number] => 20230044467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => GLYCOPEPTIDE ANTIBIOTIC COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/873269 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17873269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988886 [patent_doc_number] => 20220354923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/862086 [patent_app_country] => US [patent_app_date] => 2022-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988886 [patent_doc_number] => 20220354923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/862086 [patent_app_country] => US [patent_app_date] => 2022-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731154 [patent_doc_number] => 12209145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => PCSK9 antagonist compounds [patent_app_type] => utility [patent_app_number] => 17/854379 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25324 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17944317 [patent_doc_number] => 20220331334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Prodrug Comprising a Drug-Linker Conjugate [patent_app_type] => utility [patent_app_number] => 17/847750 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 675 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19808330 [patent_doc_number] => 12239689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Controlled-release CNP agonists with low initial NPR-B activity [patent_app_type] => utility [patent_app_number] => 17/839390 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 56179 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 944 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077373 [patent_doc_number] => 20220402985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 [patent_app_type] => utility [patent_app_number] => 17/836425 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18323697 [patent_doc_number] => 20230121825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO [patent_app_type] => utility [patent_app_number] => 17/834293 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18333446 [patent_doc_number] => 20230125394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => LYSOBACTIN FOR USE IN THE TREATMENT OF BOVINE MASTITIS [patent_app_type] => utility [patent_app_number] => 17/832868 [patent_app_country] => US [patent_app_date] => 2022-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316010 [patent_doc_number] => 12454552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof [patent_app_type] => utility [patent_app_number] => 17/832107 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 21130 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958659 [patent_doc_number] => 20220339239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY [patent_app_type] => utility [patent_app_number] => 17/831887 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316010 [patent_doc_number] => 12454552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof [patent_app_type] => utility [patent_app_number] => 17/832107 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 21130 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17928470 [patent_doc_number] => 20220323595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/804217 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17804217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018911 [patent_doc_number] => 20220370410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => Compositions and Methods for Treating Muscle Loss [patent_app_type] => utility [patent_app_number] => 17/752491 [patent_app_country] => US [patent_app_date] => 2022-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18517631 [patent_doc_number] => 11707501 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate [patent_app_type] => utility [patent_app_number] => 17/664539 [patent_app_country] => US [patent_app_date] => 2022-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 3266 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17664539 [rel_patent_id] =>[rel_patent_doc_number] =>)